H.B. Fuller Company

H.B. Fuller Company (FUL) Market Cap

H.B. Fuller Company has a market capitalization of $2.97B.

Price: $55.30

-0.08 (-0.14%)

Market Cap: 2.97B

NYSE · time unavailable

CEO: Celeste Mastin

Sector: Basic Materials

Industry: Chemicals - Specialty

IPO Date: 1973-02-21

Website: https://www.hbfuller.com

H.B. Fuller Company (FUL) - Company Information

Market Cap: 2.97B|Sector: Basic Materials

Company Profile

H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products. It operates through three segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Building Adhesive Solutions. The Hygiene, Health and Consumable Adhesives segment produces and supplies specialty industrial adhesives, such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven and hygiene, and medical and beauty. The Engineering Adhesives segment produces and supplies high performance industrial adhesives comprising reactive, light cure, two-part liquids, polyurethane, silicone, film, and fast cure products to the durable assembly, performance wood and textile, transportation, electronics, clean energy, aerospace and defense, appliance, heavy machinery, and insulating glass markets. The Construction Adhesives segment provides products used for commercial roofing, heating, ventilation, and air conditioning and insulation applications, as well as caulks and sealants for the consumer market and professional trade. The company sells its products directly to customers, as well as through distributors and retailers in North America, Latin America, Europe, India, the Middle East, Africa, and the Asia Pacific. H.B. Fuller Company was founded in 1887 and is headquartered in Saint Paul, Minnesota.

Analyst Sentiment

81%
Strong Buy

From 7 Active Polls

1Y Forecast: $66.80

▲ +20.8% Potential Upside

Consensus Target Metrics

Low Bound

$58

Median

$67

High Bound

$73

Average

$67

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$66.80
▲ +20.80% Upside
Low Target
$58.00
5% Risk
Median Target
$67.00
21% Mid
High Target
$73.00
32% Max
Consensus
Buy
9 / 15 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MMay 30, 2026Feb 28, 2026Nov 29, 2025Aug 30, 2025May 31, 2025Mar 1, 2025Nov 30, 2024Aug 31, 2024
Market Cap ($M)2,9743,4883,5973,1793,3353,0393,1214,2244,709
Enterprise Value ($M)4,9325,4465,5655,0885,2935,0555,1956,1296,599
Price to Earnings Ratio (P/E)16.2212.8243.2426.4912.4118.1259.10-7.6621.20
Price/Earnings-to-Growth Ratio (PEG)0.5586.091.31-13.12237.14
Price to Sales Ratio (P/S)0.853.674.673.553.743.383.964.575.13
Price to Book Ratio (P/B)1.451.671.741.591.701.621.762.312.56
Price to Free Cash Flow Ratio (P/FCF)21.1346.84-58.3253.8348.3838.41-36.3371.3372.23
Enterprise Value to Sales (EV/Sales)5.737.225.695.935.636.596.647.19
Enterprise Value to EBITDA (EV/EBITDA)9.6432.2951.6769.3132.6533.1055.6577.4943.52
Debt to Equity Ratio3.831.001.011.011.061.131.231.131.10

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 HB FULLER (FUL) — Investment Overview

🧩 Business Model Overview

HB Fuller is a specialty manufacturer of adhesives, sealants, and related bonding solutions sold into industrial manufacturing and construction-linked applications. The business translates formulation and application expertise into customer outcomes—improved bonding performance, faster line speeds, better durability, and compliance with evolving environmental and safety requirements.

Value creation typically follows a repeatable pattern: (1) develop application-specific adhesive/coating chemistry and dispensing processes; (2) qualify products with customers’ production lines (requiring technical documentation and trial support); (3) supply ongoing needs through a network of manufacturing sites and distribution channels; and (4) reinforce retention through continuing technical service, troubleshooting, and iterative improvements as customer processes evolve.

💰 Revenue Streams & Monetisation Model

Revenue is generated primarily from the sale of adhesives and related specialty bonding products, with monetisation driven by the product mix between commodity-like adhesive formats and higher-value specialty formulations. While sales are not “subscription” in the software sense, adhesive programs often function with embedded continuity because customers qualify suppliers and maintain line-level consistency across production volumes.

  • Specialty adhesives and systems: Higher margin profile supported by technical differentiation, formulation complexity, and application engineering.
  • General industrial adhesives: More exposed to end-market cyclicality and competitive pricing, but still supported by service and product reliability.
  • Customer technical support and formulation services: Typically bundled into commercial arrangements; the practical monetisation is realized through retained supply and expanded SKUs rather than standalone “consulting” fees.

Margin drivers are largely (1) mix shift toward specialty offerings, (2) ability to manage raw material and freight variability through pricing and sourcing, and (3) operating leverage from utilization in manufacturing footprints.

🧠 Competitive Advantages & Market Positioning

HB Fuller’s moat is best described as high switching costs—earned through qualification processes, line integration, and performance verification requirements that create friction for customers to change suppliers once manufacturing parameters are standardized.

  • Switching costs from qualification and line compatibility: Changing adhesives is not a plug-and-play event; customers require testing for bond strength, cure behavior, substrate compatibility, temperature/humidity performance, and long-term durability.
  • Application engineering as an intangible asset: HB Fuller’s technical support and know-how create repeatable value in optimizing dispensing methods, curing, and defect reduction.
  • Portfolio breadth and solution capability: A wider mix of chemistries supports cross-selling as customers move across product lines and packaging/construction formats.

COMPETITIVE BENCHMARKING

  • Henkel: A large global adhesives and surface technologies player with significant breadth across industrial segments. Henkel competes strongly on scale and system solutions; HB Fuller typically competes by emphasizing customer-specific application performance and maintaining focused technical programs.
  • 3M (industrial adhesives): A broad industrial conglomerate with deep materials science. 3M competes on innovation-driven products and diversified end-market exposure; HB Fuller competes by translating chemistry into practical line outcomes with a strong application-services model.
  • Sika (construction chemicals): A construction-focused chemicals supplier with advantages tied to project and specification-driven procurement. Sika’s construction-centric positioning differs from HB Fuller’s broader industrial adhesives emphasis, where manufacturing qualification and line economics often dominate buying decisions.

Across these rivals, the central distinction for HB Fuller is not only product availability but the execution layer—qualification support, process integration, and sustained technical collaboration that raise customer transition costs.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular themes that favor specialty adhesive suppliers with strong application capabilities.

  • Lightweighting and manufacturing efficiency: Adhesive bonding supports weight reduction versus mechanical fastening in many applications and helps enable cleaner assembly design.
  • Packaging evolution and performance requirements: Demand for higher barrier performance, better sealing, and improved throughput supports continued adhesive usage and specialty mix expansion.
  • Regulatory and sustainability-driven formulation shifts: Movement toward lower-emission and water-based/solvent-reduced chemistries rewards suppliers with formulation expertise and regulatory competence.
  • Increased automation and quality standards: Faster lines and stricter defect tolerances increase the value of supplier technical support and stable process performance.
  • Geographic expansion of manufacturing bases: Customers expanding production to new regions often require local sourcing, technical coverage, and validated product performance—areas where established supply networks can gain share.

The total addressable market expands not only through volume growth in end markets, but also through mix—customers often shift from simpler adhesive types toward specialty formulations that reduce defects, improve durability, and meet regulatory requirements.

⚠ Risk Factors to Monitor

  • End-market cyclicality: Industrial production and construction-related activities drive volume variability; resilience depends on specialty mix and pricing actions.
  • Raw material and logistics volatility: Adhesive manufacturing can be exposed to changes in key input costs and freight, requiring disciplined supply-chain management and pricing discipline.
  • Competitive intensity and qualification losses: Customer renewals and new program awards can shift with competitive bids, especially where customers value short-term cost over long-term performance.
  • Environmental and regulatory compliance costs: Reformulation to meet emission and safety standards can increase costs and create execution risk during transition.
  • Capital intensity and footprint optimization: Capacity decisions and manufacturing expansions must align with demand; underutilization can pressure margins.

📊 Valuation & Market View

The market typically values HB Fuller and peer specialty chemical businesses using EV/EBITDA or EV/EBIT metrics, with DCF frameworks that emphasize cash generation, reinvestment needs, and margin durability. Equity investors usually focus on:

  • Margin structure and mix: Specialty mix and the ability to sustain gross margin through pricing power and formulation differentiation.
  • Stability of demand and end-market diversification: Reducing the impact of cyclical swings.
  • Working capital discipline: Adhesives supply chains can be influenced by inventory and pass-through dynamics.
  • Return on invested capital: Efficiency in manufacturing utilization and disciplined capital allocation.

Multiple expansion tends to follow credibility in (1) durable specialty penetration, (2) controlled input cost pass-through, and (3) consistent execution of technical value propositions that protect retention and program wins.

🔍 Investment Takeaway

HB Fuller offers an evergreen specialty chemicals profile anchored by high switching costs and an application-engineering-led value proposition. The long-term thesis centers on maintaining specialty mix, deepening customer technical relationships that reduce churn, and capturing secular demand from lightweighting, packaging performance, and sustainability-driven formulation upgrades. The key debate for investors is whether the company can sustain margin quality and program retention through cyclical periods and competitive bidding while managing input and compliance risks.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for FUL.

zacks.com2026-07-28

4 Chemical Specialty Stocks to Gain From Demand Rebound

Improving demand in major end markets augurs well for The Zacks Chemicals Specialty industry. ESI, FUL, KWR and MTX lean on cost cuts and efficiency moves to offset persistent inflation pressures.

zacks.com2026-07-27

Is H. B. Fuller (FUL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

defenseworld.net2026-07-27

Fifth Third Bancorp Has $957,000 Stock Position in H. B. Fuller Company $FUL

Fifth Third Bancorp increased its holdings in shares of H. B. Fuller Company (NYSE: FUL) by 3,222.9% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,518 shares of the specialty chemicals company's stock after buying an additional 15,051 shares

defenseworld.net2026-07-26

H. B. Fuller Company $FUL Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its stake in H. B. Fuller Company (NYSE: FUL) by 5.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,608,006 shares of the specialty chemicals company's stock after buying an additional 132,558 shares

zacks.com2026-07-24

Why Is H. B. Fuller (FUL) Down 11% Since Last Earnings Report?

H. B. Fuller (FUL) reported earnings 30 days ago. What's next for the stock?

zacks.com2026-07-22

FUL or NVZMY: Which Is the Better Value Stock Right Now?

Investors interested in Chemical - Specialty stocks are likely familiar with H. B. Fuller (FUL) and Novozymes A/S (NVZMY).

zacks.com2026-07-21

5 Value Stocks With Impressive EV-to-EBITDA Ratios to Own Now

CLDT, PARR, ARCO, CAL and FUL stand out with attractive EV-to-EBITDA ratios and strong earnings outlook.

zacks.com2026-07-20

Why H. B. Fuller (FUL) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

gurufocus.com2026-07-16

H.B. Fuller Announces Quarterly Dividend

H.B. Fuller Company (NYSE: FUL) today announced that its Board of Directors declared a regular quarterly cash dividend of $0.2450 per share of common stock, pay

businesswire.com2026-07-16

H.B. Fuller Announces Quarterly Dividend

ST. PAUL, Minn.--(BUSINESS WIRE)--H.B. Fuller Company (NYSE: FUL) today announced that its Board of Directors declared a regular quarterly cash dividend of $0.2450 per share of common stock, payable on August 13, 2026 to shareholders of record at the close of business on July 30, 2026.H.B. Fuller has paid quarterly cash dividends on its common stock for 58 consecutive years.About H.B. FullerAs the largest pureplay adhesives company in the world, H.B. Fuller's (NYSE: FUL) innovative, functional c.

zacks.com2026-07-10

Should Value Investors Buy H. B. Fuller (FUL) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com2026-07-09

FUL Stock Is Riding Medical, Aerospace and Pricing Trends

FUL is tapping medical, aerospace and pricing trends to support margins, but volume weakness still clouds its path to stronger growth.

zacks.com2026-07-09

Is FUL Stock a Buy Now or a Value Trap for Cautious Investors?

FUL trades near the low end of its five-year valuation range as improving earnings meet volume, inflation and leverage risks tied to its medical-market expansion.

zacks.com2026-07-09

H.B. Fuller Stock Outlook Hinges on Margins, Mix and M&A

FUL's outlook rests on pricing, margins and portfolio reshaping as medical expansion and M&A aim to offset uneven demand across key end markets.

zacks.com2026-07-06

FUL vs. PPG: Which Stock Is the Better Value Option?

Investors interested in stocks from the Chemical - Specialty sector have probably already heard of H. B. Fuller (FUL) and PPG Industries (PPG).

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-05-30

"FUL reported Q2’26 revenue of $950.3M and net income of $67.8M (EPS $1.25). On a year-over-year basis, revenue was essentially flat vs Q2’25 ($950.3M vs $898.1M: +5.8%), while net income increased materially ($67.8M vs $41.8M: +62.1%). Sequentially, revenue rose to $950.3M from $770.8M in Q1’26 (+23.3%), and net income jumped from $21.0M (+222%). Profitability improved meaningfully across the quarter. Net margin expanded to 7.1% from 2.7% in the prior quarter and from 4.7% a year ago. Gross margin also improved (33.9% vs 31.3% QoQ; 33.9% vs 31.9% YoY), supporting higher operating income ($122.8M) and EBITDA ($168.6M). Cash flow quality strengthened: operating cash flow was $121.1M and free cash flow was $74.5M in Q2’26, despite paying $13.2M in dividends. Cash conversion remains solid with positive working capital contribution this quarter. Balance sheet resilience is notable: equity increased to $2.08B and total assets rose to $5.33B QoQ. Leverage remains elevated (net debt ~$1.96B), but interest coverage improved (to 3.75x from 1.85x QoQ). Shareholder returns look supportive given the stock’s 1-year gain of 23.1% and a small dividend yield (~0.38%), with continued buybacks (Q2 repurchases of ~$45.8M). Analyst targets imply upside from ~$64.43 to a consensus ~$71.50 (+~11%)."

Revenue Growth

Positive

QoQ revenue rose +23.3% (Q2’26 $950.3M vs Q1’26 $770.8M). YoY was solid +5.8% (vs Q2’25 $898.1M), indicating growth is present but not accelerating on an annual basis.

Profitability

Strong

Net margin expanded sharply to 7.1% from 2.7% QoQ and from 4.7% YoY. Net income grew +222% QoQ and +62% YoY, with improved gross and operating margins.

Cash Flow Quality

Good

Operating cash flow turned strongly positive at $121.1M and free cash flow was $74.5M in Q2’26. Dividends were paid ($13.2M) and buybacks continued, with cash generation comfortably supporting shareholder payouts in the quarter.

Leverage & Balance Sheet

Positive

Assets and equity increased QoQ ($5.33B assets; $2.08B equity), but leverage remains meaningful (net debt ~ $1.96B; debt-to-equity ~1.0). Interest coverage improved to 3.75x, improving resilience.

Shareholder Returns

Strong

Total shareholder momentum is positive: 1Y stock gain +23.1% (capital appreciation tailwind >20%). Dividend yield is modest (~0.38%) but is supported by ongoing cash flow; buybacks contributed in Q2.

Analyst Sentiment & Valuation

Positive

Consensus target ~$71.5 vs price ~$64.43 implies ~11% upside. Valuation multiples remain elevated (e.g., P/E shown ~12.8x), limiting the score despite improving fundamentals.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

FUL delivered strong Q2 2026 execution with revenue up 5.8% YoY and organic up 2.6% despite slightly lower volume, as pricing (+3%) and restructuring offset cost pressures. EBITDA grew 9% to $181M and margin expanded 70 bps to 19.1%, while adjusted gross margin rose 200 bps to 34.2%. Cash generation was strong (CFO $121M; record 2Q) and net working capital improved 260 bps sequentially. Management updated FY2026 guidance upward at the midpoint for both EBITDA ($650M–$675M) and EPS ($4.60–$4.90), while maintaining revenue growth targets and cash flow outlook ($300M–$325M). The headline event is the announced GBP 715M all-cash acquisition of AMS, with quantified run-rate synergies of ~$55M (including Peters Surgical in-flight synergies) expected to be ~50% realized by 2028 and full cost synergies by 2030. Leverage rises temporarily but management targets 2.5–3.0x within two years of close. Near-term outlook excludes AMS impact, and macro supply disruption risk persists.

AI IconGrowth Catalysts

  • Pricing actions gaining traction; Q2 organic pricing +3% offset slightly lower volume (organic +2.6%)
  • Quantum Leap restructuring initiative strengthening competitiveness and supporting margin expansion
  • Improved sequential volume trends vs Q1 despite petrochemical supply chain disruption

Business Development

  • Announced all-cash offer to acquire Advanced Medical Solutions (AMS): GBP 2.85 per share; ~GBP 715 million enterprise value
  • AMS integration synergy linkage to in-flight Peters Surgical integration synergies

AI IconFinancial Highlights

  • Revenue +5.8% YoY; organic revenue +2.6% YoY (pricing +3% offset by slightly lower volume)
  • EBITDA $181M, +9% YoY; EBITDA margin expanded +70 bps to 19.1%
  • Adjusted gross margin 34.2%, +200 bps YoY (pricing execution + restructuring savings)
  • Adjusted SG&A +11% YoY; ex-FX and excluding higher variable compensation, SG&A ~+3%
  • Adjusted EPS $1.41, +19% YoY
  • Net working capital 16.4% of annualized net revenue, down 260 bps sequentially
  • Cash flow from operations $121M record 2Q; 2026 delivery weighted to 2H
  • Capital return: repurchased ~750,000 shares in Q2

AI IconCapital Funding

  • Share repurchases: ~750,000 shares in Q2
  • Net debt / adjusted EBITDA 3.1x (Q2 end), down from 3.4x a year ago
  • AMS funding: incremental debt financing; ~GBP 1B committed acquisition financing
  • Leverage expectations: exit FY2026 2.8–2.9x prior to close; pro forma net leverage at close ~4.0x excluding run-rate synergies
  • Deleveraging target: return to 2.5–3.0x within two years of closing

AI IconStrategy & Ops

  • Supply continuity maintained via global sourcing organization; pricing actions ramping into back half
  • No rapid normalization expected for global supply chains; risk of intermittent shortages persists into 2H
  • Segment profitability execution: HHC EBITDA margin 17.9% (+230 bps YoY); BAS organic sales +6% YoY
  • Guidance update explicitly excludes AMS impact for near-term outlook

AI IconMarket Outlook

  • FY2026 net revenue: still expected mid-single digits up YoY; organic low single digits up vs FY2025
  • FY2026 FX translation: positively impact revenue by 1%–2%
  • FY2026 adjusted EBITDA: $650M–$675M (midpoint increased)
  • FY2026 adjusted EPS: $4.60–$4.90 (midpoint increased)
  • FY2026 operating cash flow: $300M–$325M
  • Q3 2026: net revenue up mid-single digits YoY; adjusted EBITDA $180M–$190M
  • AMS deal guidance exclusion: stated that current outlook does not reflect AMS acquisition

AI IconRisks & Headwinds

  • Middle East conflict aftershocks expected; no rapid recovery of global supply chains; intermittent shortages risk remains in 2H
  • Raw material costs expected not to retrace to pre-disruption levels (inflationary reset of industry cost structure)
  • Demand environment being monitored carefully; volumes cautious given inflationary interest-rate environment
  • AMS execution/regulatory risk: close targeted end of calendar year 2026 subject to regulatory + AMS shareholder approval
  • Leverage temporarily above target range post-announcement, though management cites a deleveraging path

Q&A: Analyst Interest

  • Topic: AMS deal fit vs “pure-play adhesives” narrative and potential divestitures. Management: will continue characterizing as pure-play adhesives; majority of AMS business is adhesives/tapes and portfolio remains “differentiated formulator.” Strategic review covers whole portfolio fit/performance/value vs capital allocation requirements, and may include actions such as further portfolio evaluation like prior flooring divestiture if objectives aren’t met.
  • Topic: AMS synergy realism, especially cost synergy magnitude and what makes it higher than prior deals. Management: cost synergy is higher than other deals; example Royal at ~7%–8% of revenue vs AMS ~11%–12%. Two drivers: public-company cost burden in AMS and inclusion of in-flight Peters Surgical cost synergies (~$14M) raising the normalized number.
  • Topic: AMS margin expectations vs “40% EBITDA” medical pockets and the role of Peters Surgical and scale. Management: combined business expected >30% EBITDA margin after synergies. AMS currently burdened by public-company overhead/scale. Wound care segment is most challenging; adhesives-driven synergies and operating leverage improve it, plus Peters Surgical plant consolidations (suture five-to-one; collagen two-to-one) should accelerate margin improvement.

Sentiment: MIXED

Note: This summary was synthesized by AI from the FUL Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for FUL.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (FUL)

© 2026 Stock Market Info — H.B. Fuller Company (FUL) Financial Profile